Table 2.

Overview of clinical findings in 269 living and 43 deceased patients and their relative prognostic value assessed by OR.

ClinicalTotal, nLiving, nDeceased, nOR (95% CI)p
PAH/PH3417179.6 (4.3–21.1)< 0.001
ILD9874243.6 (1.8–7.2)< 0.001
dcSSc6851172.8 (1.4–5.5)0.001
Male6954152.1 (1.1–4.3)0.01
ACA169153160.4 (0.2–0.8)0.004
  • PAH: pulmonary arterial hypertension; PH: pulmonary hypertension; ILD: interstitial lung disease; dcSSc: diffuse cutaneous systemic sclerosis; ACA: anticentromere antibody.